AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3780987 — intervention group
Group type: COMPARATOR
Intervention: Breast conserving treatment (tumorectomy followed by radiotherapy)
Number of subjects: 0
Study 3780987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (mastectomy and breast conserving treatment)
Number of subjects: 0
Study 29655257 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 10
Study 29655257 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 27466252 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 457
Study 27466252 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with oxygen cannula (DLO2)
Number of subjects: 457
Study 27466252 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with Truview PCD videolaryngoscope (VLO2)
Number of subjects: 457
Study 25088437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (target HbA1c less than 42 mmol/mol or less than 6·0%)
Number of subjects: 10251
Study 25088437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 10251
Study 25088437 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (target HbA1c 53‐63 mmol/mol or 7·0‐7·9%)
Number of subjects: 10251
Study 22343976 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80-85% 1RM (85%)
Number of subjects: 12
Study 22343976 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60-65% 1RM (65%)
Number of subjects: 12
Study 22343976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise intensities
Number of subjects: 12
Study 20186278 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 for 5 consecutive days every 8 weeks for 3 cycles
Number of subjects: 267
Study 20186278 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus ART for 5 consecutive days every 8 weeks for 3 cycles with 10 days of ART around each IL-2 cycle
Number of subjects: 267
Study 20186278 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 267
Study 18499354 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 361
Study 18499354 — intervention group
Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 361
Study 15980686 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/ritonavir (RTV)‐containing highly active antiretroviral (ARV) therapy regimens
Number of subjects: 0
Study 12705178 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole (10 mg/kg body weight, two consecutive oral doses)
Number of subjects: 32
Study 12705178 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclabendazole (10 mg/kg body weight) + Vitamin C (1000 mg/day) + Vitamin E (600 mg/day) for two months
Number of subjects: 32
Study 12705178 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 healthy subjects)
Number of subjects: 32
Study 10589540 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 36
Study 10589540 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study 8756736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-antitrypsin activity in blood after operation in patients with prostatic carcinoma
Number of subjects: 0
Study 8756736 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-antitrypsin activity in blood after operation in patients with benign prostatic hyperplasia
Number of subjects: 0
Study 8756736 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8756736 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic carcinoma
Number of subjects: 0
Study 2017331 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 40
Study 2017331 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 40
Study 6784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg twice a day
Number of subjects: 55
Study 6784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 250 mg four times a day
Number of subjects: 55
Study 6784224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 mg every 8 hr
Number of subjects: 55
Study 6784224 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 30698316 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1212
Study 30698316 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG (MED/CABG)
Number of subjects: 1212
Study 30698316 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CCI score
Number of subjects: 1212
Study 30698316 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between CCI score and treatment effect
Number of subjects: 1212
Study 28854580 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU recombinant FSH (rFSH)
Number of subjects: 124
Study 26346470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD), containing 12.5 μg/250 ml, taken twice a day for 12 weeks
Number of subjects: 60
Study 26346470 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD), containing no vitamin D, taken twice a day for 12 weeks
Number of subjects: 60
Study 23287836 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) - 12 weeks of supervised squat exercise, 3 times a week
Number of subjects: 21
Study 23287836 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 21
Study 23287836 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - encouraged to follow current exercise guidelines
Number of subjects: 21
Study 22724916 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 14
Study 22724916 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study 19585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED) in training combat support hospital (CSH) setting
Number of subjects: 0
Study 19585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED) in combat forward operating base (FOB) setting
Number of subjects: 0
Study 19585769 — intervention group
Group type: COMPARATOR
Intervention: Standard manual defibrillation in training combat support hospital (CSH) setting
Number of subjects: 0
Study 19585769 — intervention group
Group type: COMPARATOR
Intervention: Standard manual defibrillation in combat forward operating base (FOB) setting
Number of subjects: 0
Study 19585769 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated External Defibrillator (AED)
Number of subjects: 0
Study 17965789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation (lactulose 2 days before surgery and rectal enema on the day of surgery)
Number of subjects: 127
Study 17965789 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (Control Group II)
Number of subjects: 127
Study 15379121 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy consisting of 5-day courses of cytostatic drugs alternating or not alternating with 5-day courses of ATRA
Number of subjects: 68
Study 15379121 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 68
Study 15379121 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hyperleukocytosis
Number of subjects: 68
Study 15379121 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 68
Study 11803986 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossAction toothbrush
Number of subjects: 91
Study 11803986 — intervention group
Group type: COMPARATOR
Intervention: X‐Aktiv toothbrush
Number of subjects: 91
Study 10990440 — intervention group
Group type: EXPERIMENTAL
Intervention: GH secretagogues
Number of subjects: 0
Study 10990440 — intervention group
Group type: COMPARATOR
Intervention: GH79
Number of subjects: 0
Study 3164341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study 3164341 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30620688 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the eustachian tube (BDET) + medical management (MM)
Number of subjects: 143
Study 27041109 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave‐One instrumentation (G3)
Number of subjects: 96
Study 27041109 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal instrumentation (G2)
Number of subjects: 96
Study 27041109 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation (G1)
Number of subjects: 96
Study 26287319 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PCF) with surgery
Number of subjects: 346
Study 26287319 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy alone
Number of subjects: 346
Study 22992376 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 70
Study 21076271 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-active antiretroviral therapy (ART) for 48 weeks
Number of subjects: 16
Study 21076271 — intervention group
Group type: COMPARATOR
Intervention: HIV-HBV co-infected patients
Number of subjects: 16
Study 18640000 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored-feedback intervention promoting the Mediterranean diet
Number of subjects: 53
Study 18640000 — intervention group
Group type: COMPARATOR
Intervention: Minimal dietary feedback and general healthy-eating brochures (Control)
Number of subjects: 53
Study 17056969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 60
Study 17056969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12712958 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX vaccine
Number of subjects: 0
Study 10736331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) - 10 g/d
Number of subjects: 38
Study 10736331 — intervention group
Group type: COMPARATOR
Intervention: Triacylglycerol (TG) - 10 g/d (control)
Number of subjects: 38
Study 8737101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g MgSO4 bolus followed by 4 g MgSO4 for 24 h
Number of subjects: 29
Study 8737101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g MgSO4 bolus followed by 14 g MgSO4 for 24 h
Number of subjects: 29
Study 8737101 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 29
Study 1560192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement treatment
Number of subjects: 30
Study 1560192 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 30
Study 1560192 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal conditions (before oophorectomy)
Number of subjects: 30
Study 1560192 — intervention group
Group type: EXPERIMENTAL
Intervention: One month after oophorectomy
Number of subjects: 30
Study 2862464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powdered surfactant (25 mg) insufflated through the endotracheal tube
Number of subjects: 56
Study 2862464 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 30879731 — intervention group
Group type: EXPERIMENTAL
Intervention: High prenatal social support
Number of subjects: 262
Study 29603805 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance band training
Number of subjects: 99
Study 29603805 — intervention group
Group type: COMPARATOR
Intervention: General physical exercise
Number of subjects: 99
Study 27055221 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK surgery
Number of subjects: 32
Study 27055221 — intervention group
Group type: COMPARATOR
Intervention: Control group (cataract patients)
Number of subjects: 32
Study 24981461 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxycodone
Number of subjects: 39
Study 24981461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23163142 — intervention group
Group type: EXPERIMENTAL
Intervention: Qudu Granule (QG), orally taken, 5 g each time, 3 times a day for over 12 months.
Number of subjects: 166
Study 23163142 — intervention group
Group type: COMPARATOR
Intervention: Niaoduqing granule (NG), orally taken, 5 g each time, 3 times a day for over 12 months.
Number of subjects: 166
Study 23163142 — intervention group
Group type: EXPERIMENTAL
Intervention: Qudu Granule (QG)
Number of subjects: 166
Study 23163142 — intervention group
Group type: COMPARATOR
Intervention: Niaoduqing granule (NG)
Number of subjects: 166
Study 20380284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy with Temodal (75 mg/m2)
Number of subjects: 179
Study 20380284 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy only (60 Gy, fractionated into 5 x 2 Gy weekly)
Number of subjects: 179
Study 20380284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Chemo-radiotherapy and RT)
Number of subjects: 179
Study 20380284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy with Temodal
Number of subjects: 179
Study 18083668 — intervention group
Group type: EXPERIMENTAL
Intervention: Care from respiratory nurse
Number of subjects: 187
Study 18083668 — intervention group
Group type: COMPARATOR
Intervention: Usual care from respiratory physician
Number of subjects: 187
Study 15653517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus strain L-92 (100 mL of heat-treated fermented milk)
Number of subjects: 49
Study 15653517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acidified milk without lactic acid bacteria)
Number of subjects: 49
Study 12567031 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized facilitation of motor-evoked potentials
Number of subjects: 20
Study 12567031 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid motor-evoked potentials
Number of subjects: 20
Study 12567031 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in motor-evoked potential amplitude
Number of subjects: 20
Study 10235522 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia containing 2 mM adenosine and adenosine infusion (200 microg/kg/min) before and after aortic crossclamp removal
Number of subjects: 253
Study 10235522 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia containing 2 mM adenosine
Number of subjects: 253
Study 10235522 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 253
Study 8909453 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human ciliary neurotrophic factor (rhCNTF) at doses ranging from 2 to 100 micrograms/kg
Number of subjects: 72
Study 8909453 — intervention group
Group type: COMPARATOR
Intervention: daily subcutaneous rhCNTF at doses < or = 5 micrograms/kg/day
Number of subjects: 72
Study 8909453 — intervention group
Group type: EXPERIMENTAL
Intervention: daily subcutaneous rhCNTF at higher doses
Number of subjects: 72
Study 1810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% meclofenamic acid gel
Number of subjects: 90
Study 1810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium meclofenamate capsules
Number of subjects: 90
Study 1810522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1810522 — intervention group
Group type: COMPARATOR
Intervention: Sodium naproxen capsules
Number of subjects: 90
Study 6406441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 150 mg/day
Number of subjects: 63
Study 6406441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 450 mg/day
Number of subjects: 63
Study 6406441 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 63
Study 6406441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30521423 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic hypercapnia (NH)
Number of subjects: 31
Study 30521423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic hypercapnia (HH)
Number of subjects: 31
Study 30521423 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 31
Study 30521423 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 31
Study 30081458 — intervention group
Group type: EXPERIMENTAL
Intervention: Annoyance due to aircraft noise
Number of subjects: 1244
Study 30081458 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise sensitivity
Number of subjects: 1244
Study 30081458 — intervention group
Group type: COMPARATOR
Intervention: Exposure to aircraft noise in dB
Number of subjects: 1244
Study 27021017 — intervention group
Group type: EXPERIMENTAL
Intervention: Power nap: 10-20 min sleep
Number of subjects: 35
Study 27021017 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nap: 50-80 min sleep
Number of subjects: 35
Study 27021017 — intervention group
Group type: COMPARATOR
Intervention: Wake condition: 45-min wake
Number of subjects: 35
Study 24858886 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental tobacco prevention intervention
Number of subjects: 520
Study 22869581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 2 mg/kg/day for 7 days
Number of subjects: 143
Study 22869581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 4 mg/kg/day for 7 days
Number of subjects: 143
Study 22869581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy at 6 mg/kg/day for 7 days
Number of subjects: 143
Study 22869581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate monotherapy
Number of subjects: 143
Study 20962434 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 20962434 — intervention group
Group type: EXPERIMENTAL
Intervention: SC‐70303
Number of subjects: 0
Study 17055329 — intervention group
Group type: EXPERIMENTAL
Intervention: APO (apomorphine) at typically effective dose (TED)
Number of subjects: 62
Study 17055329 — intervention group
Group type: EXPERIMENTAL
Intervention: APO+2 (apomorphine at TED+0.2mL)
Number of subjects: 62
Study 17055329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) at volume equal to TED
Number of subjects: 62
Study 17055329 — intervention group
Group type: COMPARATOR
Intervention: Placebo+2 (PL+2 at volume equal to TED+0.2mL)
Number of subjects: 62
Study 14530901 — intervention group
Group type: COMPARATOR
Intervention: Memantine (0 mg)
Number of subjects: 18
Study 14530901 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (15 mg)
Number of subjects: 18
Study 14530901 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (30 mg)
Number of subjects: 18
Study 11815315 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-kernel rye bread
Number of subjects: 20
Study 11815315 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-meal rye bread containing oat beta-glucan concentrate
Number of subjects: 20
Study 11815315 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark durum wheat pasta
Number of subjects: 20
Study 11815315 — intervention group
Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 20
Study 9710711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 35 mg ethinylestradiol and 2 mg cyproterone acetate
Number of subjects: 67
Study 9710711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 30 mg ethinylestradiol and 150 mg desogestrel
Number of subjects: 67
Study 7663660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised rhDNase 2.5 mg twice daily
Number of subjects: 70
Study 7663660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7663660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised rhDNase 2.5 mg twice daily (open-label phase)
Number of subjects: 70
Study 7663660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open-label phase)
Number of subjects: 70
Study 2667508 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 271
Study 65660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 4031
Study 65660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4031
Study 31445481 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine auditory‐verbal approach plus new cognitive-based intervention protocol
Number of subjects: 51
Study 31445481 — intervention group
Group type: COMPARATOR
Intervention: Routine auditory‐verbal approach
Number of subjects: 51
Study 27869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (0.005% ointment) combined with 5-fluorouracil (5% cream)
Number of subjects: 131
Study 27869649 — intervention group
Group type: COMPARATOR
Intervention: Vaseline plus 5-fluorouracil (5% cream)
Number of subjects: 131
Study 26384238 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide
Number of subjects: 235
Study 26384238 — intervention group
Group type: COMPARATOR
Intervention: ATRA and idarubicin
Number of subjects: 235
Study 23644718 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive Coolgard(®) cooling
Number of subjects: 80
Study 23644718 — intervention group
Group type: COMPARATOR
Intervention: Non‐invasive ArcticSun(®) surface cooling
Number of subjects: 80
Study 21593096 — intervention group
Group type: EXPERIMENTAL
Intervention: Full length 5 degree lateral wedged insoles worn daily for 12 months
Number of subjects: 200
Study 21593096 — intervention group
Group type: COMPARATOR
Intervention: Flat control insoles worn daily for 12 months
Number of subjects: 200
Study 19389040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16621098 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-subtype recombinant genome
Number of subjects: 61
Study 16621098 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LTRs
Number of subjects: 61
Study 15245943 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SpA)
Number of subjects: 72
Study 15245943 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 72
Study 11726007 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25 (Mix25)
Number of subjects: 172
Study 11726007 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (GB)
Number of subjects: 172